This is a clinical marketing press release, not a financial earnings report. No revenue, EPS, or guidance data was disclosed. Monitor upcoming quarterly filings for any impact on Advanced Wound Management segment sales. No immediate trading action warranted.
Price Chart
Executive Summary
Smith+Nephew published a press release announcing a new German consensus-based clinical guidance for single-use negative pressure wound therapy (sNPWT) in closed surgical incisions, supported by the PICO 7 system. The release is a clinical marketing update, not a financial earnings report, no revenue, EPS, or guidance data were provided.
Key Facts
- New German consensus-based clinical guidance for sNPWT in closed surgical incisions published in Die Chirurgie.
- Guidance identifies at-risk patients (obesity, diabetes, smoking, prolonged surgery) for sNPWT use.
- Smith+Nephew's PICO 7 sNPWT system is highlighted as the device supporting the guidance.
- No financial data, revenue, EPS, or guidance was provided in this press release.
Financial Impact
No financial data provided; clinical guidance publication may support future PICO 7 adoption but no immediate revenue impact quantified.
Risk Factors
- Clinical guidance does not guarantee increased adoption or revenue.
- No financial data provided, cannot assess business performance from this release.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3324547 |
Track record
42 reports on SNN
6 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +8.02% at T+20 after the Jun 30, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 1/10 Entry $31.00 Now $30.97 −0.10% settles Nov 19
- Nov 4, 202612d ago 6-K Bearish 6/10 No price data
- Nov 4, 202612d ago 6-K Bearish 6/10 Entry $32.46 to $31.04 Now $30.97 +4.59% ▲ +4.37% +3.46% vs SPY
- Nov 2, 202614d ago 6-K Neutral 4/10 Entry $30.24 to $31.05 Now $30.97 +2.41% ▲ +2.68% +2.60% vs SPY
- Oct 22, 202625d ago 6-K Neutral 2/10 Entry $30.88 to $30.22 Now $30.97 +0.29% ▼ −2.14% −2.84% vs SPY
- Oct 8, 20265w ago 6-K Neutral 2/10 Entry $26.96 to $29.09 Now $30.97 +14.87% ▲ +7.90% +8.18% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers